Montreux, Switzerland | September 14, 2023 –Le CNRS Innovation, établi en 1992, est l’organisme national chargé de la valorisation et du transfert de technologie du
Montreux, Switzerland | July 27, 2023 –CYTEA|BIO, a pre-clinical stage biotech company developing therapeutic antibody-effector cell constructs, is proud to announce the submission of documents for a pre-IND meeting
Montreux, Switzerland | June 7, 2023 – CYTEA|BIO, a pre-clinical stage biotech company developing therapeutic antibody-effector cell constructs, is pleased to announce the formation of its Clinical Steering Group
Nous avons eu le privilège de rencontrer Madame Sylvie Retailleau, ministre de l’Enseignement supérieur et de la Recherche. Cet échange nous a permis de partager
Montreux, Switzerland | April 4, 2023 – MedXCell SA, a European venture builder that specializes in cell therapy for major diseases such as cancer, autoimmune,
Montreux, Switzerland | November 2, 2022 – CYTEA|BIO, a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies combining non genetically modified effector cells (such as
This website contains information about products that may not be available in all countries, available under different trademarks or for different indications. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development and described on this site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider
© All rights reserved 2022 – MedXCell SA
